HPV vaccine may be cost-effective strategy for preventing oropharyngeal cancer in males
the ONA take:
According to a new study published online early in the journal Cancer, researchers from Princess Margaret Cancer Centre in Toronto, Ontario, Canada, have found that vaccinating adolescent boys against the human papillomavirus (HPV) may be a cost-effective approach for preventing squamous cell oropharyngeal cancer.
For the study, researchers applied a statistical model to a population of over 190,000 Canadian boys who were 12 years old in 2012. Results showed that the HPV vaccination could save $8 million to $28 million Canadian dollars over the boys' lifetimes.
The findings of this study are important because HPV-related oropharygneal cancer is projected to become the most common HPV-related cancer in the United States by 2020.
The authors of the study hope that the findings of this study will increase public awareness and persuade policymakers across the world to fund the HPV vaccination in boys.
HPV vaccinations, such as Gardasil, are known to be effective at reducing the risk of cervical, vulvar, vaginal, and anal cancer in females, and anal cancer in males.
HPV vaccine may be a cost-effective approach for preventing squamous cell oropharyngeal cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|